Anticancer treatment for uveal melanoma
Provided herein are methods for treating uveal melanoma in a subject in need thereof by administering an effective amount of an agent that inhibits expression of FAK protein to the subject. In one aspect, the agent that inhibits expression of FAK protein comprises, or alternatively consists essentially of, or yet further consists of a gene editing agent, such as for example one or more of: RNA interference (RNAi), CRISPR/Cas, ZFN, and/or TALEN. In another aspect, the agent is VS-4718. Also described herein are kits comprising, or alternatively consisting essentially of, or yet further consisting of one or more of: agents that inhibit expression of FAK protein, siRNAs, shRNAs, miRNAs, nucleases and/or guide RNA sequences for carrying out the methods of this disclosure, and optional instructions for use.
1. A method for treating primary or metastatic uveal melanoma (UM) in a subject in need thereof comprising administering an effective amount of a first agent that inhibits expression of focal adhesion kinase (FAK) and a second agent that inhibits mitogen-activated protein kinase kinase (MEK), wherein the first agent is one or more of: PF-562271, VS-4718, NVP-TAC544, TAE226, VS-6063, 1H-Pyrrolo(2,3-b)pyridine, Y15 (1,2,4,5-benzenetetraamine tetrahydrochloride), chloropyramine hydrochloride, R2, Y11, PF-562,271, or GSK2256098 and wherein the second agent is one or more of: selumetinib, trametinib, cobimetinib, CH5126766, Binimetinib, AZD-8330, PD-325901, CI-1040, or TAK-733.
2. The method of claim 1 , wherein the UM of the subject has one or more of: a deficient GTPase, a constitutively active Gaq protein, an increased expression of Yes-Associated Protein (YAP), a nuclear-localized YAP, an increased phosphorylation of YAP at Y357, a decreased phosphorylation of YAP at S127, a reduced expression of BAP1, or an increased expression of FAK protein.
3. A method for treating primary or metastatic uveal melanoma (UM) in a subject in need thereof comprising administering an effective amount of a first agent that inhibits expression of focal adhesion kinase (FAK) and a second agent that inhibits mitogen-activated protein kinase kinase (MEK), wherein the first agent is VS-4718 and the second agent is trametinib or CH5126766.
4. A method for treating primary or metastatic uveal melanoma (UM) in a subject in need thereof comprising administering an effective amount of a first agent that inhibits expression of focal adhesion kinase (FAK) and a second agent that inhibits mitogen-activated protein kinase kinase (MEK), wherein the first agent is VS-6063 and the second agent is CH5126766.
5. The method of claim 1 , wherein the subject in need thereof is a mammal.
6. The method of claim 5 , wherein the mammal is human being.
7. The method of claim 1 , wherein the administering an effective amount of the first agent and the second agent comprises one or more of: oral, topical, transdermal, intranasal, vaginal, rectal, subcutaneous intravenous, intraarterial, intramuscular, intraosseous, intraperitoneal, intraocular, subconjunctival, sub-Tenon's, intravitreal, retrobulbar, intracameral, intratumoral, epidural and intrathecal.
8. The method of claim 1 , wherein the administering an effective amount of the first agent and the second agent occurs simultaneously.
9. A method for selecting a subject having uveal melanoma (UM) or suspected of having uveal melanoma for treatment with the method of claim 1 , the method comprising one or more of the following: 1) determining if a biological sample isolated from the subject has or is characterized as: a deficient GTPase, 2) a constitutively active Gαq protein, 3) an increased expression of Yes-Associated Protein (YAP), 4) a nuclear-localized YAP, 5) an increased phosphorylation of YAP at Y357, 6) a decreased phosphorylation of YAP at S127, 7) a reduced expression of BAP1, or 8) an increased expression of FAK protein.